Having trouble accessing articles? Reset your cache.

Bydureon exenatide regulatory update

EMA said that it is evaluating the potential pancreatic toxicity of glucagon-like peptide-1 (GLP-1) receptor ( GLP-1R; GLP1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. Last month, FDA said it was evaluating the potential pancreatic toxicity of antidiabetics (see BioCentury, March

Read the full 402 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE